Patients undergoing surgical resection of primary breast tumors confront a risk for metastatic recurrence that peaks sharply 12 to 18 months after surgery. (stm.sciencemag.org)
In preclinical tests in mice, a team at CSHL was able to dramatically change the character of an aggressive, metastatic primary breast tumor by targeting a single long non-coding RNA called Malat1 with a candidate drug called an antisense oligonucleotide (ASO). (sciencedaily.com)
On the other hand, overexpression of miR7 significantly decreased the mammosphere - forming ability of primary breast tumor cells (Fig. 5D). (cancerres.aacrjournals.org)